Full-Time

Clinical Trials Assistant

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Compensation Overview

$42 - $47/hr

+ Bonus + Incentives + Restricted Stock Units

Junior, Mid

San Bruno, CA, USA

This is an onsite, full-time position with a schedule of Monday - Friday.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • 2 years’ experience in medical research, laboratory, histology, IVD, nursing or the biopharmaceutical industry
  • Excellent problem-solving skills; demonstrated strength intact and diplomacy with internal and external collaborators
  • Excellent written and oral communication skills
  • Ability to work independently and exercise good judgment
  • Excellent teamwork and collaborations skills
Responsibilities
  • Act as point of contact to coordinate clinical study supply shipments and receive/return study samples
  • Document samples shipped and received according to protocol, and accurately document chain of custody
  • Work with laboratory personnel to ensure that sample receipt, sample management and tracking is managed according to Standard Operating Procedures
  • Process and store samples according to protocol or move into testing workflow
  • Accurately enter clinical data received in study case report forms or appropriate clinical database(s)
  • Other duties can be assigned
Desired Qualifications
  • Experience with clinical trials operations, data management, site management or regulatory coordination preferred
  • Preferred minimum of one year laboratory experience, specifically specimen processing

Veracyte specializes in cancer diagnostics by developing advanced genomic tests for early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into cancer presence and progression. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve cancer diagnosis accuracy, enhance patient outcomes, and optimize the use of medical resources.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Increasing demand for personalized medicine boosts genomic diagnostics growth.
  • AI integration enhances accuracy and speed of Veracyte's cancer diagnostics.
  • Regulatory support is improving for genomic testing, streamlining approvals.

What critics are saying

  • AI-based tests may have bias due to initial development on limited demographics.
  • MRD assay launch in 2026 may face reimbursement challenges with commercial payers.
  • ClearLab's 2026 launch may encounter significant market competition.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
MLO Online
Feb 17th, 2025
New Data at ASCO demonstrates the performance and clinical utility of Veracyte's Decipher Prostate and Decipher Bladder tests

Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.

Investing.com
Sep 4th, 2024
Veracyte expands board with two new members

SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Stock Titan
Sep 4th, 2024
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.